Genmab — December 2017
-
har i set, at TF-ADC bliver startet op i et combo fase 2 cervical cancer - FRONT LINE i 2018
-
https://www.einpresswire.com/article/415530342/actinium-pharmaceuticals-launches-the-awe-program-aka-actinium-warhead-enabling-program-to-enable-collaborations-based-on-its-actinium-225-technology Forstår ikke at enten Genmab eller JNJ allerede har en aftale her.
-
det står ikke i ASH præsentationen. Kan at der vil blive staret fase II
-
Det blev annonceret 10/10. Fase 2 TV mono mod livmoderhalskræft. Muligt godkendelsesstudie. http://ir.genmab.com/releasedetail.cfm?ReleaseID=1043270
-
Har vi ikke snakket om det før?
-
tf-adc i frontline combo - på side 114 i ASH præsentationen http://files.shareholder.com/downloads/AMDA-KPIBN/5458124093x0x966499/E1B59AE9-20C1-4087-87FD-3A4E99F5435A/RandD_Update_vFinal_Website.pdf (under 2018 goals)
-
http://alfarim.com/actinium-225/ Der er flere interessante selskaber
-
bulder - det ser ud til, at GEN vil starte 2 fase II studier på tf-adc
-
måske derfor de guidede så elendigt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind